evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract,articles/15/pmid,articles/15/title,articles/15/journal,articles/15/pubDate,articles/15/volume,articles/15/issue,articles/15/pages,articles/15/authors,articles/15/elocationId,articles/15/link,articles/15/reference,articles/15/abstract,articles/16/pmid,articles/16/title,articles/16/journal,articles/16/pubDate,articles/16/volume,articles/16/issue,articles/16/pages,articles/16/authors,articles/16/elocationId,articles/16/link,articles/16/reference,articles/16/abstract,articles/17/pmid,articles/17/title,articles/17/journal,articles/17/pubDate,articles/17/volume,articles/17/issue,articles/17/pages,articles/17/authors,articles/17/elocationId,articles/17/link,articles/17/reference,articles/17/abstract,articles/18/pmid,articles/18/title,articles/18/journal,articles/18/pubDate,articles/18/volume,articles/18/issue,articles/18/pages,articles/18/authors,articles/18/elocationId,articles/18/link,articles/18/reference,articles/18/abstract
4760,GENE_SUMMARY,,MDM4 encodes a negative regulator of the p53 tumor suppressor. MDM4 is amplified or overexpressed in a diverse range of cancers resulting in aberrant p53 activity.,,2017-03-01,,4194,MDM4,"MDM4, p53 regulator",True,ENST00000367182,NM_002393.4,MRP1,HDMX,MDMX,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4761,GENE_BACKGROUND,,"The MDM4 gene encodes a negative regulator of the p53 tumor suppressor, the most frequently inactivated gene in human cancer (PMID: 25960041, 22154076). The two major negative regulators of p53, MDM2 and MDM4, function by blocking its N-terminal transactivation domain (PMID: 21730163). In addition, MDM4 stimulates the MDM2-catalysed ubiquitination of p53 which leads to its degradation (PMID: 14507994, 12162806). Similar to MDM2, MDM4 is deregulated in several tumor types such as cutaneous melanoma, primary breast tumors, retinoblastomas (PMID: 17080083), Ewing sarcomas (PMID: 21098696) and gliomas (PMID: 22820643, 15199139, 12640683, 11280734). In the overwhelming majority of cases, cells with deregulated MDM2 or MDM4 retain wild-type p53 (PMID: 23303139). Thus, inhibition of the p53 interaction with MDM2 or MDM4 is an attractive candidate strategy for treatment of cancer via the reactivation of p53 (PMID: 25621298, 21098696, 20080970, 14704432, 25201201, 23374098, 16905541, 16540668).",,2017-03-01,,4194,MDM4,"MDM4, p53 regulator",True,ENST00000367182,NM_002393.4,MRP1,HDMX,MDMX,False,25621298,MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation.,Oncoscience,2014,True,12,830-43,Hirose M et al,,,Hirose M et al. Oncoscience. 2014;1(12)830-43.,,12162806,MDMX inhibits the p300/CBP-mediated acetylation of p53.,DNA and cell biology,2018-07-01T20:02:00,21,7,519-25,Sabbatini P et al,,,0001-07-01,,17080083,Inactivation of the p53 pathway in retinoblastoma.,Nature,2018-11-02T20:06:00,444,7115,1961-06-01,Laurie NA et al,,,0001-11-02,,14507994,HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.,Proceedings of the National Academy of Sciences of the United States of America,2018-10-14T20:03:00,100,21,12009-14,Linares LK et al,,,0001-10-14,,12640683,Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target.,International journal of cancer,2018-05-10T20:03:00,104,6,752-7,Riemenschneider MJ et al,,,0001-05-10,,15199139,Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.,Molecular and cellular biology,2018-07-01T20:04:00,24,13,5835-43,Danovi D et al,,,0001-07-01,,14704432,In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.,"Science (New York, N.Y.)",2018-02-06T20:04:00,303,5659,844-8,Vassilev LT et al,,,0001-02-06,,21730163,The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.,Proceedings of the National Academy of Sciences of the United States of America,2018-07-19T20:11:00,108,29,12001-6,Huang L et al,doi: 10.1073/pnas.1102309108,,0001-07-19,,16905541,MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.,The Journal of biological chemistry,2018-11-03T20:06:00,281,44,33030-5,Hu B et al,,,0001-11-03,,22154076,Deconstructing p53 transcriptional networks in tumor suppression.,Trends in cell biology,2018-02-01T20:12:00,22,2,97-106,Bieging KT et al,doi: 10.1016/j.tcb.2011.10.006,,2018-02-01T01:06:00,,20080970,Identification and characterization of the first small molecule inhibitor of MDMX.,The Journal of biological chemistry,2018-04-02T20:10:00,285,14,10786-96,Reed D et al,doi: 10.1074/jbc.M109.056747,,0001-04-02,,25960041,Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation.,Trends in cell biology,2018-08-01T20:15:00,25,8,486-95,Gurpinar E et al,doi: 10.1016/j.tcb.2015.04.001,,0001-08-01,,21098696,Nutlin-3a is a potential therapeutic for ewing sarcoma.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-02-01T20:11:00,17,3,494-504,Pishas KI et al,doi: 10.1158/1078-0432.CCR-10-1587,,2018-02-01T05:04:00,,11280734,Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.,Cancer research,2018-03-01T20:01:00,61,5,1839-42,Ramos YF et al,,,0001-03-01,,25201201,Targeting p53-MDM2-MDMX loop for cancer therapy.,Sub-cellular biochemistry,2014,85,,281-319,Zhang Q et al,doi: 10.1007/978-94-017-9211-0_16,,Zhang Q et al. Sub-cellular biochemistry. 2014;85()281-319.,,23374098,Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).,Expert opinion on therapeutic patents,2018-04-01T20:13:00,23,4,425-48,Zak K et al,doi: 10.1517/13543776.2013.765405,,0001-04-01,,23303139,"MDM2, MDMX and p53 in oncogenesis and cancer therapy.",Nature reviews. Cancer,2018-02-01T20:13:00,13,2,83-96,Wade M et al,doi: 10.1038/nrc3430,,0001-02-01,,22820643,MDM4 is a key therapeutic target in cutaneous melanoma.,Nature medicine,2018-08-01T20:12:00,18,8,1239-47,Gembarska A et al,doi: 10.1038/nm.2863,,0001-08-01,,16540668,Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.,Cancer research,2018-03-15T20:06:00,66,6,3169-76,Patton JT et al,,,0001-03-15,
